Prescribing to fit the needs of older people - The NHS Scotland polypharmacy guidance, 2nd edition

Journal of the Royal College of Physicians of Edinburgh

Volumn 45, Issue 2, 2015, Pages 108-113

  Wilson, M ^a   Mair, A ^b   Dreischulte, T ^c   Witham, M D ^d  

^a NHS HIGHLAND   (United Kingdom)

^b SCOTTISH GOVERNMENT   (United Kingdom)

^c NHS TAYSIDE   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Guidelines; Multimorbidity; Polypharmacy; Prescribing

Indexed keywords

ARTICLE; COMPREHENSION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIFE EXPECTANCY; MEDICATION COMPLIANCE; PATIENT DECISION MAKING; PATIENT EDUCATION; PATIENT SELECTION; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT INDICATION; AGED; CLINICAL PRACTICE; GERIATRICS; NATIONAL HEALTH SERVICE; STANDARDS; UNITED KINGDOM;

AGED; GERIATRICS; HUMANS; POLYPHARMACY; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; SCOTLAND; STATE MEDICINE;

EID: 84932627578     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2015.204     Document Type: Article

References (13)

1. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-9.
2. Howard RL, Avery AJ, Slavenburg S et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007; 63: 136-47.
3. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24: 46-54.
4. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing 2013; 42: 62-9. http:// dx.doi.org/10.1093/ageing/afs100
5. Barnett K, Mercer SW, Norbury M et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37-43. http://dx.doi.org/10.1016/S0140-6736(12)60240-2
6. Scottish Government Model of Care Polypharmacy Working Group. Polypharmacy Guidance. 2nd ed. Edinburgh: Scottish Government; 2015.
7. Gallagher P, Ryan C, Byrne S et al. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 2008; 46: 72-83.
8. Dreischulte T, Grant AM, McCowan C et al. Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement. BMC Clin Pharmacol 2012; 12: 5. http:// dx.doi.org/10.1186/1472-6904-12-5
9. Spencer R, Bell B, Avery AJ et al. Identification of an updated set of prescribing-safety indicators for GPs. Br J Gen Pract 2014; 64: e181-90. http://dx.doi.org/10.3399/bjgp14X677806
10. British Geriatrics Society. Fit for Frailty. Consensus best practice guidance for the care of older people living in community and outpatient settings. June 2014. http://www.bgs.org.uk/campaigns/fff/ fff_full.pdf (accessed 20/4/2015).
11. Patterson SM, Cadogan CA, Kerse N et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 2014; 10: CD008165. http://dx.doi. org/10.1002/14651858.CD008165.pub3
12. Habicht DW, Witham MD, McMurdo ME. The under-representation of older people in clinical trials: barriers and potential solutions. J Nutr Health Aging 2008; 12: 194-6.
13. Saini P, Loke YK, Gamble C et al. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ 2014; 349: g6501. http://dx.doi.org/10.1136/bmj. g6501